[1]
|
Hutter, G., Nowak, D., Mossner, M., Ganepola, S., Mussig, A., Allers, K., Schneider, T., Hofmann, J., Kucherer, C., Blau, O., Blau, I.W., Hofmann, W.K. and Thiel, E. (2009) Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. New England Journal of Medicine, 360, 692-698.
|
[2]
|
Liu, R., Paxton, W.A., Choe S., Ceradini, D., Martin, S.R., Horuk, R., MacDonald, M.E., Stuhlmann, H., Koup, R.A. and Landau, N.R. (1996) Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell, 86, 367-377. doi:10.1016/S0092-8674(00)80110-5
|
[3]
|
Beatty, P.G., Boucher, K.M., Mori, M. and Milford, E.L. (2000) Probability of finding HLA-mismatched related or unrelated marrow or cord blood donors. Human Immunology, 61, 834-840.
zdoi:10.1016/S0198-8859(00)00138-5
|
[4]
|
Majhail, N.S., Brunstein, C.G., Tomblyn, M., Thomas, A.J., Miller, J.S., Arora, M., Kaufman, D.S., Burns, L.J., Slungaard, A, McGlave, P.B., Wagner, J.E., Weisdorf, D.J. (2008) Reduced-intensity allogeneic transplant in patients older than 55 years: Unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biology of Blood and Marrow Transplantation, 14, 282-289. doi:10.1016/j.bbmt.2007.12.488
|
[5]
|
Kleen, T.O., Kadereit, S., Fanning, L.R., Jaroscak, J., Fu, P., Meyerson, H.J., Kulchycki, L., Slivka, L.F., Kozik, M., Tary-Lehmann, M. and Laughlin, M.J. (2005) Recipient-specific tolerance after HLA-mismatched umbilical cord blood stem cell transplantation. Transplantation, 80, 1316-1322. doi:10.1097/01.tp.0000188172.26531.6f
|
[6]
|
Verlinsky, Y., Strelchenko, N., Kukharenko, V., Shkumatov, A., Rechitsky, S., Verlinsky, O. and Kuliev, A. (2006) Repository of human embryonic stem cell lines and development of individual specific lines using stembrid technology. Reproductive BioMedicine Online, 13, 547-550.
|
[7]
|
Verlinsky, Y., Strelchenko, N., Kukharenko, V., Shkumatov, A., Rechitsky, S., Verlinsky, O. and Kuliev, A. (2009) Isolation of human embryonic stem cells from various stages of the human embryo. In: Lakshmipathy et al. Ed, Emerging Technology Platforms for Stem Cells, Wiley, Hoboken, 19-27. doi:10.1016/S1472-6483(10)60643-8
|
[8]
|
Robertson, N.J., Brook, F.A., Gardner, R.L., Cobbold, S.P., Waldmann, H. and Fairchild, P.J. (2007) Embryonic stem cell-derived tissues are immunogenic but their inherent immune privilege promotes the induction of tolerance. Proceeding of the National Academy Science of the USA, 104, 20920-20925.
|
[9]
|
Wu, D.C., Boyd, A.S. and Wood, K.J. (2008) Embryonic stem cells and their differentiated derivatives have a fragile immune privilege but still represent novel targets of immune attack. Stem Cells, 26, 1939-1950.
doi:10.1634/stemcells.2008-0078
|
[10]
|
Verlinsky, Y. and Kuliev, A. (2006) Practical preimplantation genetic diagnosis. Springer, London and New York, 198.
|
[11]
|
Martinson, J.J., Chapman, N.H., Rees, D.C., Liu, Y.T. and Clegg, J.B. (1997) Global distribution of the CCR5 gene 32-basepair deletion. Nature Genetics, 16, 100-103.
doi:10.1038/ng0597-100
|
[12]
|
Taylor, C. Bolton, E., Procock, S., Sharples, L., Pederson, R. and Bradley, J. (2005) Banking of human embryonic stem cells: Estimating the number of donor cell lines needed for HLA matching. Lancet, 366, 2019-2025.
doi:10.1016/S0140-6736(05)67813-0
|
[13]
|
Pryzhkova, M.V., Peters, A. and Zambidis, E.T. (2010) Erythropoietic differentiation of a human embryonic stem cell line harbouring the sickle cell anemia mutation. Reproductive BioMedicine Online, 21, 196-205.
doi:10.1016/j.rbmo.2010.04.017
|